Overview

Patients with recurrent renal cell cancer have cancer that has progressed with treatment or returned after being previously treated. Renal cell cancers may recur locally, in the area of the kidney, or in other parts of the body such as the lungs or bones.

Recurrent renal cell cancers are typically treated with systemic therapy and some may also be treated with local therapy. Systemic therapy is directed at destroying cancer cells throughout the body, and includes targeted therapies such as Nexavar® (sorafenib), Sutent® (sunitinib), Torisel® (temsirolimus), Afinitor® (everolimus), Avastin® (bevacizumab), Votrient™ (pazopanib), and Inlyta® (axitinib). In addition, some patients may benefit from local therapy consisting of surgery to remove areas of metastatic disease.

The following is a general overview of conventional and investigative treatments for recurrent renal cell cancer. Cancer treatment may consist of surgery, targeted therapy, or a combination of these treatment techniques. Combining two or more of these treatment techniques has become an important approach for increasing a patient’s chance of cure and prolonging survival.

In some cases, participation in a clinical trial utilizing new, innovative therapies may provide the most promising treatment. Treatments that may be available through clinical trials are discussed in the section titled Strategies to Improve Treatment.

Circumstances unique to each patient’s situation influence which treatment or treatments are utilized. The potential benefits of combination treatment, participation in a clinical trial, or standard treatment must be carefully balanced with the potential risks. The information on this Web site is intended to help educate patients about their treatment options and to facilitate a mutual or shared decision-making process with their treating cancer physician.

Systemic Therapy for Recurrent Renal Cell Cancer

Systemic therapy refers to whole-body therapy. In patients with recurrent renal cell cancer, systemic therapy is administered in order to control the disease and its symptoms and to prolong life.  The choice of which systemic therapy or therapies to use will depend on how the cancer was treated previously. For recurrent renal cell cancer, physicians typically recommend a therapy that has not already been used to treat the cancer.

Examples of systemic therapies that are commonly used in the treatment of renal cancer include;

Immunotherapy for Recurrent Renal Cell Cancer: Immunotherapy works by stimulating the immune system to fight the cancer. The two most frequently used types of immunotherapy are Proleukin® (aldesleukin; also known as interleukin-2) and interferon alfa.

Proleukin® (interleukin-2): Prior to the FDA-approval of new targeted therapies, Proleukin was the standard of care for patients with renal cell cancer. It is typically administered in high doses as an inpatient treatment and has historically been associated with severe side effects. However, the safety of high-dose Proleukin has significantly improved over the past decade.

Unfortunately, long-term results of clinical trials indicate that only approximately 15% of patients with advanced renal cell carcinoma have an anticancer response when treated with high-dose Proleukin.1 For this reason the combination of targeted therapy plus Proleukin is being evaluated in clinical trials.

Interferon: Interferon is naturally produced in the body and stimulates the immune system. Interferon alfa is a compound produced in a laboratory that mimics the action of natural interferon and has been shown to stimulate the immune system to recognize and destroy some types of cancer cells.

Treatment of renal cell carcinoma with interferon alfa appears to produce anticancer responses in less than 15% of patients with advanced renal cell cancer. Because side effects can be severe and it has not been shown to improve survival, the use of interferon alone in the treatment of renal cell carcinoma remains controversial.

Targeted Therapy for Recurrent Renal Cell Cancer: A targeted therapy is one that is designed to treat only the cancer cells and minimize damage to normal, healthy cells. The advantages of cancer treatments that “target” cancer cells may include reduced treatment-related side effects and improved outcomes.

Sutent (sunitinib): Sutent is an oral multi-targeted tyrosine kinase inhibitor that targets proteins responsible for stimulating cancer cell growth.  Two Phase II clinical trials have shown that approximately 40% of patients with recurrent renal cell cancer respond to treatment with Sutent, and approximately one-quarter of patients experienced stable disease for three months after treatment.2

Nexavar (sorafenib): A Phase III clinical trial compared Nexavar to placebo in more than 900 patients with previously-treated, advanced renal cell cancer. Treatment with Nexavar significantly improved progression-free survival (survival without a worsening of the cancer). Progression-free survival was 5.5 months for those treated with Nexavar compared with 2.8 months for those who received placebo.3 A later analysis of these data also suggested that Nexavar significantly improved overall survival.4 Based on the results of this study, Nexavar was FDA-approved for use in renal cell cancer.

Torisel (temsirolimus): The clinical trial that prompted FDA approval of Torisel included 626 patients with metastatic RCC who had a poor prognosis and had not received prior therapy.5 Patients were treated with either Torisel, interferon alfa, or a combination of Torisel plus interferon alfa (combination group).

  • Patients treated with Torisel had longer survival by nearly 3.6 months and significantly longer progression-free survival than patients treated with interferon alone.
  • Patients in the combination group did not experience a significant improvement in survival compared with patients treated with interferon alone.
  • Fewer patients suffered from severe side effects in the group treated with Torisel than in the group treated with interferon.

Avastin (bevacizumab): Avastin is a targeted therapy that blocks a protein known as VEGF. VEGF plays a key role in the development of new blood vessels. By blocking VEGF, Avastin deprives the cancer of nutrients and oxygen and inhibits its growth. For patients with metastatic kidney cancer, treatment with a combination of Avastin and interferon alfa results in a longer time to cancer progression than treatment with interferon alpha alone.6

Votrient (pazopanib): Votrient is a targeted oral medication known as an angiogenesis inhibitor. The drug may help slow or prevent the growth of new blood vessels, which deprives the cancer of the oxygen and nutrients it needs to grow. The approval of Votrient for advanced kidney carcinoma was prompted in part by a Phase III clinical trial showed that the drug delayed cancer progression.7

Afinitor (everolimus): Afinitor is an oral medication that works by inhibiting a protein known as mTOR. The mTOR protein plays an important role in regulating cancer cell division and blood vessel growth. Afinitor may be used for the treatment of advanced kidney cancer that has progressed after treatment with Sutent® (sunitinib) or Nexavar® (sorafenib).

Inlyta (axitinib): Inlyta is a drug that is taken orally, as a pill. It works by blocking certain proteins that play a role in cancer growth. Inlyta has been shown to delay cancer progression among patients with advanced renal cell cancer that worsens in spite of initial treatment with another drug.8

Chemotherapy for Recurrent Renal Cell Cancer: Chemotherapy is any treatment involving the use of drugs to kill cancer cells. Cancer chemotherapy may consist of single drugs or combinations of drugs and can be administered through a vein or delivered orally in the form of a pill. Renal cell cancers have historically been resistant to treatment with chemotherapy; only 10–15% of patients experience an anticancer response to currently available single chemotherapy drugs.

Surgery for Renal Cell Cancer

Some patients with recurrent renal cell cancer may benefit from surgery. Results of a clinical trial indicate that renal cell cancer that has spread to the lungs can be removed with surgery. Among patients with lung metastases but no evidence of cancer elsewhere in the body, including the kidney, nearly 40% survived five years or more after undergoing surgery for the lung metastases. Patients with only a single site of cancer in the lung experienced the best outcomes; nearly 50% survived five years or more compared with 19% of patients who had more than one site of cancer removed. 9

Radiation Therapy for Recurrent Renal Cell Cancer

Recurrent renal cell cancers may be treated with radiation therapy to relieve the symptoms such as pain or bleeding. Typically, renal cell cancers are resistant to radiation therapy, which means that this approach will not eliminate the cancer, but it may temporarily slow its growth and relieve associated discomforts.

Managing Bone Complications

Renal cell cancer may spread to the bone.  Bone metastases may cause pain, bone loss, an increased risk of fractures, and a life-threatening condition characterized by a high level of calcium in the blood, called hypercalcemia.

Drugs that may be used to reduce the risk of complications from bone metastases include bisphosphonates and Xgeva® (denosumab). Bisphosphonates, such as Zometa® (zoledronic acid), work by inhibiting bone resorption, or breakdown. Xgeva targets a protein known as the RANK ligand. This protein regulates the activity of osteoclasts (cells that break down bone).

To learn more about bone metastases and bone health, go to Bone Complications and Cancer

Strategies to Improve Treatment

The development of more effective cancer treatments requires that new and innovative therapies be evaluated with cancer patients. Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. Future progress in the treatment of renal cell cancer will result from the continued evaluation of new treatments in clinical trials.

Patients may gain access to better treatments by participating in a clinical trial. Participation in a clinical trial also contributes to the cancer community’s understanding of optimal cancer care and may lead to better standard treatments. Patients who are interested in participating in a clinical trial should discuss the risks and benefits of clinical trials with their physician. Areas of active investigation aimed at improving the treatment of renal cell cancer include the following:

Combination Therapy: Combinations of chemotherapy drugs, called regimens, may produce more anticancer responses and improve the outcomes of patients with advanced renal cell cancer than treatment with any single therapy. Combination therapy can take advantage of potential drug synergies and non overlapping side effects to improve clinical benefit. Clinical trials are ongoing evaluating combinations of Avastin, newer targeted therapies, and immunotherapy in order to determine whether combinations can improve the outcome of patients compared with the use of any single drug.

Vaccines for Renal Cell Cancer: Vaccines are comprised of proteins that stimulate the immune system to destroy foreign substances in the body, such as bacteria. Vaccines are also being developed that stimulate the immune system to recognize cancer cells as harmful and destroy them. Cancer vaccines are typically made from proteins that are more abundantly present on cancer cells than normal cells. The patient’s own cancer cells are often used to make the vaccine, which is one reason that vaccines may be difficult to prepare. The patient’s cancer cells must be processed immediately following surgery. Therefore, patients and their surgeons must prepare in advance to ensure that the removed cancer cells can be handled properly for vaccine preparation.

Laparoscopic Surgery: Laparoscopic surgery is a technique that is less extensive and invasive than traditional, open surgery. During a laparoscopic surgery for renal cancer, the surgeon makes small, one-centimeter incisions in the abdomen and side. A very small tube that holds a video camera is inserted to create a live picture of the inside of the patient’s body. This picture is continually displayed on a television screen, allowing the surgeon to perform the entire surgery by watching the screen. For a radical nephrectomy, the incision is enlarged to allow passage of the kidney.

In the treatment of metastatic renal cell cancer, laparoscopic surgery appears to be associated with less blood loss, fewer transfusions, and shorter hospitalization compared with open nephrectomy. In addition, there were no increases in complications with laparoscopy and patients were able to proceed with systemic therapy with this approach.10

References


1 Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. Journal of Clinical Oncology. 1995;13(3):688-696.

2 George D, Motzer R, Rini B, et al. Sunitinib malate (SU11248) shows antitumor activity in patients with metastatic renal cell carcinoma: updated results from Phase II trials. Proceedings from the 2005 annual Chemotherapy Foundation Symposium. New York, NY. Abstract #18.

3 Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal cell cancer. New England Journal of Medicine. 2007; 356:125-34.

4 Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. Presented at the 2007 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. Abstract 5023.

5 Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. New England Journal of Medicine. 2007; 356:2271-2281.

6 Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-11.

7 Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology. 2010;28:1061-1068.

8 Rini BI, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. Paper presented at: 2011 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2011; Chicago, IL. Abstract 4503.

9 Friedel G, Hurtgen M, Penzenstadler M, et al. Resection of pulmonary metastases from renal cell carcinoma. Anticancer Research. 1999;19(2C):1593-1596.

10 Eisenberg MS, Meng MV, Master VA et al. Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. J Endourol 2006 Jul;20(7):504-8.

Copyright ©; 2014 Omni Health Media Renal Cancer Information Center. All Rights Reserved.